Vertex Pharma (VRTX) Misses Q3 EPS by 9c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Vertex (VRTX) PT Lifted to $180 at Piper Jaffray as KALYDECO and ORKAMBI Both Beat
October 29, 2015 7:56 AM EDTPiper Jaffray analyst Edward Tenthoff reiterated an Overweight rating and boosted his price target on Vertex (NASDAQ: VRTX) to $180.00 (from $163.00) following solid Q3 results with KALYDECO and ORKAMBI both beating.
Tenthoff commented, "Over 3,000 patients began ORKAMBI in 3Q:15 resulting in sales of $130.8 million,... More
Baird Positive on First Quarter of Vertex (VRTX) Orkambi Sales
October 29, 2015 6:58 AM EDTBaird analyst Brian Skorney reiterated an Outperform rating and $160 price target on Vertex (NASDAQ: VRTX) following results saying they are bullish on first quarter of Orkambi sales.
Skorney commented, "Right off the bat, Orkambi commanded ~35% of the patients eligible for treatment, according... More
